Drug Profile

CV 15

Alternative Names: CV-15; ICP-NI

Latest Information Update: 28 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cellivery
Developer Cellivery; Labcorp Drug Development
Class Anti-inflammatories; Antivirals; Macromolecular substances; Peptides
Mechanism of Action Nuclear importation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Immunological disorders

Most Recent Events

28 Jul 2024 No recent reports of development identified for preclinical development in Immunological-disorders in South Korea
17 May 2023 Cellivery Therapeutics suspends a phase I as sponsor decides to hold trial (In volunteers) in USA (IV, Injection) (NCT05740280)
19 Jan 2023 Phase-I clinical trials in Immunological disorders (In volunteers) in USA (IV) (NCT05740280)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com